BCM
BML Capital Management Portfolio holdings
AUM
$131M
This Quarter Return
-9.69%
1 Year Return
+89.45%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$137M
AUM Growth
-$12.8M
(-8.6%)
Cap. Flow
+$1.34M
Cap. Flow
% of AUM
0.98%
Top 10 Holdings %
Top 10 Hldgs %
85.49%
Holding
35
New
3
Increased
10
Reduced
3
Closed
6
Top Buys
| 1 |
Adverum Biotechnologies
ADVM
|
$7.77M |
| 2 |
Aclaris Therapeutics
ACRS
|
$3.95M |
| 3 |
Atea Pharmaceuticals
AVIR
|
$2.78M |
| 4 |
Vanda Pharmaceuticals
VNDA
|
$2.25M |
| 5 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$2.18M |
Top Sells
Sector Composition
| 1 | Healthcare | 65.21% |
| 2 | Technology | 1.44% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KLRS
26
Kalaris Therapeutics, Inc. Common Stock
KLRS
$80.6M
| $436K | 0.31% |
26,221
+17,505
| +201% | +$291K |
|
|
TLIS
27
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
| $370K | 0.26% |
42,743
| – | – |
|
28
Abercrombie & Fitch
ANF
$4.41B
| – | – |
0
| – | – |
|
29
Enliven Therapeutics
ELVN
$1.24B
| – | – |
-50,100
| Closed | -$881K |
|
30
Wingstop
WING
$8.95B
| – | – |
0
| – | – |
|
31
Q32 Bio
QTTB
$20.2M
| – | – |
-24,894
| Closed | -$424K |
|
|
ORKA
32
Oruka Therapeutics, Inc. Common Stock
ORKA
$567M
| – | – |
-58,911
| Closed | -$1.24M |
|
|
CLYM
33
Climb Bio, Inc. Common Stock
CLYM
$163M
| – | – |
-2,193,742
| Closed | -$6.01M |
|
|
KNTE
34
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| – | – |
-498,851
| Closed | -$1.33M |
|
|
CYT
35
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| – | – |
-3,654,053
| Closed | -$11M |
|